NCT05733715View on ClinicalTrials.gov

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

January 31, 2028

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Pembrolizumab infusion

100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)

DRUG

Lenvatinib tablet

10mg and 4mg daily for 21 days

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center at University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER